Bausch Health and Lannett have settled a decadelong lawsuit regarding claims the drugmakers colluded to inflate generic drug prices, according to court documents filed in the U.S. District Court for the District of Connecticut.
In agreeing to pay nearly $18 million combined, the two drugmakers on Feb. 2 settled allegations of conspiring “to fix prices and allocate markets for many generic drugs” in violation of antitrust laws and consumer protection laws, according to the settlement.
Originally filed in 2016, the lawsuit’s plaintiff list expanded over the years to include 44 states, the District of Columbia, Puerto Rico, the Virgin Islands and the Northern Mariana Islands. The states not part of the lawsuit are Alabama, Arkansas, Hawaii, Louisiana, Missouri and Texas.
Lannett will pay $13.8 million and Bausch will pay $4.1 million, and both will implement internal reforms to ensure compliance with antitrust laws, including annual training of sales and management staff.
The larger, ongoing lawsuit lists dozens of drug manufacturers and senior pharmaceutical executives as defendants.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
